Major Victory for Bayer's Monsanto as Appeals Court Overturns $185 Million Award in Chemical Exposure Case 
Adidas Strategizes to Sustain Sneaker Sales Surge as Samba, Gazelle Drive Growth 
Ferrari Unveils New 12Cilindri Models, Bolstering Its Petrol-Powered Lineup 
Anthropic Launches Claude AI App on iPhone to Rival OpenAI’s ChatGPT 
Tesla Granted South Korean Emission Credit Trading Rights by Environmental Ministry 
Comcast Drops Bally Sports Channels, Stops Broadcast of MLB Team Games 
Indian Coca-Cola Bottler HCCB Eyes IPO Amid Expansion and Growth Opportunities 
Mercedes-Benz Financial Appoints Korean Unit’s CEO 
Tesla Drivers Get $4k Off 2024 Chevy Blazer EV; Costco Auto Slashes Prices on New EVs 
China set to blast off to the far side of the Moon – here’s what it could discover 
Boeing’s Starliner is about to launch − if successful, the test represents an important milestone for commercial spaceflight 
Dongfeng Unveils High-Power Tesla Cybertruck Rival, Eyes Production in Italy 
Sony Pictures, Apollo Looking to Jointly Acquire Paramount, Propose $26 Billion Cash Deal 
Samsung Chief Lee Jae-yong Wraps Up Europe Visit, Includes Vatican and Zeiss 
Kakao Enhances AI Focus, Merges Kakao Brain Into Core Operations 
Kellanova Beats Expectations with Strong Q1 Sales Amid Higher Prices 
Jordan Brand Wings Unveils Air Jordan I Mid Subway, Celebrating NYC's MTA Crews 
EAST RUTHERFORD, N.J., Oct. 31, 2017 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that third quarter 2017 financial results will be released on Tuesday, November 7, 2017 before the market opens.
The Company will host a conference call to discuss the financial results.
| Third Quarter 2017 Earnings Conference Call | |
| When: | Tuesday, November 7, 2017 at 8:30 a.m. Eastern Time |
| Dial-in: | 1-866-548-4713 for U.S. |
| 1-323-794-2093 for International | |
| Passcode: 1511082 | |
| Dial-in Replay: | 1-888-203-1112 for U.S. |
| 1-719-457-0820 for International | |
| Passcode: 1511082 | |
| Available through Tuesday, November 14, 2017 | |
| Webcast: | www.cambrex.com |
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com.
Contact:
Stephanie LaFiura
Investor Relations Associate
Tel: 201-804-3037
Email: [email protected]
